DiaMedica Files 20-F Registration Statement with U.S. SEC and Provides Clinical Update
19 2월 2014 - 10:30PM
Marketwired
DiaMedica Files 20-F Registration Statement with U.S. SEC and
Provides Clinical Update
MINNEAPOLIS, MINNESOTA--(Marketwired - Feb 19, 2014) -
Minneapolis, Minnesota - DiaMedica (TSX-VENTURE:DMA) announced that
it has filed a Registration Statement on Form 20-F to register its
common shares with the United States Securities and Exchange
Commission (the "SEC"). The filing is subject to review by the
SEC.
"The registration of our common shares with the SEC is an
important step in the process to be listed on a U.S. securities
exchange," said Rick Pauls, President & CEO of DiaMedica.
"Listing on a national U.S. stock exchange will enhance our
exposure to the large U.S. biotech investment community."
DiaMedica's registration filing with the SEC follows successful
completion of its Phase 1 program for DM199, which included 50
healthy volunteers. The Phase 1 program clearly demonstrated the
safety and tolerability of DM199 along with supporting the
potential for weekly dosing. Subsequently, in a single ascending
dose study in Type 2 diabetic patients, DM199 showed a positive
trend towards improved insulin sensitivity compared to placebo
patients as measured by HOMA2-IR. HOMA2-IR is a measurement of
insulin resistance, a primary component of Type 2 diabetes
reflecting the body's inability to effectively process glucose
leading to hyperglycemia (high blood glucose). Specifically, over
the 8-day period, HOMA2-IR levels improved or stabilized in the 7
DM199 treated patients and worsened in the 3 placebo treated
patients suggesting a potential insulin sensitization effect. DM199
is currently being evaluated in a Phase 2 clinical trial in 36 Type
2 diabetic patients who are sequestered over a one-month treatment
period. Results from the Phase 2 study are expected in 2014.
A Form 20-F, once declared effective by the SEC, allows certain
foreign issuers to register securities with the SEC pursuant to
applicable U.S. securities laws.
About DiaMedica
DiaMedica Inc. is a publicly traded (TSX-VENTURE:DMA) clinical
stage biopharmaceutical company focused on the discovery and
development of novel therapies to treat diabetes and the
complications associated with diabetes. DiaMedica's lead clinical
stage compound, DM199, is a recombinant human protein known as
rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel
monoclonal antibody, DM204 for the treatment of Type 2 diabetes,
which is in preclinical development.
The Company is listed on the TSX Venture Exchange in Canada
under the trading symbol 'DMA'.
FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not
historical facts contain forward-looking information that involves
risk and uncertainties. All statements, other than statements of
historical facts, which address DiaMedica's expectations, should be
considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions
made by and information currently available to management. When
used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar
import, are intended to identify any forward-looking statements.
You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities
regulatory authorities. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation
undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of any unanticipated events.
Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
DiaMedica Inc.Rick PaulsChairman &
CEO763-710-4455info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024